Week in Review: CFDA to Outsource Drug Reviews

The CFDA will begin outsourcing reviews for drug approvals to speed up the process and consider a priority review system for important new generics; Skystar Bio-Pharma, a Xi’an veterinary medicine company, raised $5 million for acquisitions and in-licensing; Welichem Biotech of Canada ended its attempt to buy back China rights to a topical psoriasis treatment; CASI Pharma of the US received CFDA permission to start a China Phase II trial of a novel cancer drug; Berry Genomics, a Beijing company, is seeking CFDA approval for its noninvasive prenatal test; Merck KGaA will break ground in August on its new $108 million Shanghai manufacturing plant; BGI Tech Solutions launched a human whole exome sequencing service at a cost of $599 per sample; and China Cord Blood will cooperate with Singapore’s Cordlife Group to find suitable donors in each other’s umbilical cord blood stem cell banks. More details…. Stock Symbols: (NSDQ: SKBI) (TSX-V: WBI) (NSDQ: CASI) (Xetra: MRK) (NYSE: CO) (SGX: CLGL) Share this with colleagues: // //